Phase 2 Glaucoma Trial, Recruiting NCT05180994 Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) Condition: Glaucoma
Back to Glaucoma

Phase 2 Glaucoma Trial, Recruiting

NCT05180994
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 80 years old
  • You are scheduled for your first-ever corneal transplant surgery (surgery to replace the clear front part of the eye)
  • You are able to understand and agree to the terms of the study
  • You are able to apply eye drops yourself, or you have a caregiver who is able and willing to do this for you

Who may not be able to join:

  • You currently have an active eye infection
  • You have previously had a corneal transplant of any kind
  • You have advanced glaucoma (a serious eye pressure condition) or advanced macular disease (a serious condition affecting central vision)
  • You have an active or past infection with certain serious illnesses, including tuberculosis, histoplasmosis, coccidioidomycosis, cytomegalovirus, pneumocystis, aspergillosis, or hepatitis B
  • You have been diagnosed with any type of cancer in the past 5 years
  • You have a disease that affects the protective coating around your nerves (called a demyelinating disease)
  • You have diabetes (whether controlled or not) or a serious heart condition classified as stage III or IV
  • You are currently pregnant or breastfeeding
  • You have a known allergy to infliximab or any ingredient in its eye drop formulation
  • You have significant abnormalities in your blood count or liver enzyme test results
  • You are currently taking or have previously taken anti-TNF-α medications or other biologic anti-inflammatory treatments (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Marie-Claude Robert, MD, CHUM

Phone: 514 890-8000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Registry
ClinicalTrials.gov
Start date
1 May 2022
Est. completion
1 March 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Complications associated to PKP surgery; Complications associated to infliximab use

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov